Sign in
Taking people in United StatesPhase 1

Pentamidine added to modified FOLFIRINOX for advanced pancreatic cancer

Tests pentamidine with modified FOLFIRINOX as first treatment for advanced pancreatic cancer.

Key facts

Who runs it
University of Oklahoma
Where
Oklahoma City, United StatesSee the site
Trial code
Registry title
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Status
Recruiting
Phase
Phase 1
People taking part
30 people, planned
Started
6 Oct 2026
Expected to end
Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • modified FOLFIRINOX
  • Pentamidine 300 MG Injection
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced, unresectable or metastatic pancreatic cancer who have not yet had chemotherapy for metastatic disease.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Confirmed locally advanced, unresectable and/or metastatic pancreatic cancer, with at least one measurable tumour (RECIST v1.1).
Earlier treatment
No earlier systemic anti-cancer treatment (chemotherapy, small molecule or biologic) in the metastatic setting before the first dose of study drug.

Main reasons for not taking part

  • Active bacterial infection
  • Pregnant or nursing women, or women planning pregnancy
  • Heart rhythm problems or heart failure (QTc >480 msec, NYHA Grade 2 or higher)
  • Severe or uncontrolled illness, such as uncontrolled hypertension or diabetes, or active hepatitis B, hepatitis C or HIV
  • Another active invasive cancer within 2 years before screening

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Written informed consent signed and dated by the patient
  • At least 18 years-of-age at the time of signature of the informed consent form (ICF)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Patients with a confirmed diagnosis of locally advanced, unresectable and/or metastatic pancreatic cancer
  • Patients must have at least one measurable disease per RECIST v1.1,
  • Patients must have at least 1 tumor lesion amenable to biopsy and must be willing to undergo a biopsy prior to first treatment and after receiving 8th cycle of therapy
  • Adequate bone marrow function defined as ANC> 1000/μL and platelets>75,000/μL
  • Adequate liver function defined as total bilirubin<1.5g/L
  • Adequate renal function defined as creatinine <1.5ULN or creatinine clearance greater than 30 ml/m2
  • AST and ALT <2.5x ULN or AST and ALT<5xULN if liver function abnormalities are due to liver metastases
  • Male or female patients. Male patients with female partners of childbearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following the last dose. Male patients must also refrain from donating sperm during their participation in the study
  • Life expectancy ≥ 3 months according to the Investigator's judgment

Who cannot take part

  • Any systemic anti-cancer chemotherapy, small molecule, biologic, or from a previous treatment regimen or clinical study in a metastatic setting before the first dose of study drug
  • Presence of other active invasive cancers other than the one treated in this study within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment
  • Active bacterial infection
  • As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active infection requiring treatment including hepatitis B, hepatitis C, and human immunodeficiency virus. Screening for chronic conditions is not required
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol
  • Any of the following cardiac criteria currently or within the last 6 months:; Mean resting corrected QT interval (QTc) >480 msec; Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third degree heart block; Congestive heart failure (New York Heart Association ≥ Grade 2; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
  • Women who are pregnant, nursing, or who plan to become pregnant while in the study and for at least 6 months after the last administration of study treatment
  • Men who plan to father a child while in the study and for at least 6 months after the last administration of study treatment
  • Incidences of chronic hypokalemia that cannot be corrected
  • Prisoners

Where in United States

  • University of Oklahoma Health CampusOklahoma City, United StatesContact: Susanna Ulahannan, MDTaking people

About the trial

What the trial wants to find out

The purpose of this research is to observe the effects of using a new combination of drugs to inhibit tumor growth.

The 2 groups in the trial

  • modified FOLFIRINOXExisting treatment, for comparison

    In Arm A (up to 15 patients) will be treated with modified FOLFIRINOX every two weeks, delivered as follows: * Oxaliplatin 85mg/m2 IV over 2 hours on Day 1, followed by, * Irinotecan 150mg/m2 IV over 90 minutes on Day 1, followed by * Leucovorin 400mg/m2 IV over 2 hours on Day 1, followed by * 5FU 2400mg/m2 IV over 46-48 hours on Days 1-3 Patients will be treated over eight two-week cycles, and the entire treatment is expected to last approximately 4 months.

  • modified FOLFIRINOX + PentamidineTreatment being tested

    In arm B patients (up to 15), the same modified FOLFIRINOX regimen will be used, as above, plus 300 mg pentamidine will be administered IV over a one-hour infusion on Day 1 of each cycle. Patients will be treated over eight two-week cycles, and the entire treatment is expected to last approximately 4 months.

    Treatment: modified FOLFIRINOX and Pentamidine 300 MG Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
Plain-language title
Pentamidine added to modified FOLFIRINOX for advanced pancreatic cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026